Jazz Pharmaceuticals presents data from Erwinaze safety trial Jazz Pharmaceuticals announced that data from the largest safety trial to date of patients treated with Erwinaze have been presented at the American Society of Hematology Annual Meeting and Exposition. The poster presentation is based on results of a compassionate use protocol in patients who received Erwinaze as part of a multi-agent chemotherapeutic regimen for acute lymphoblastic leukemia who developed a hypersensitivity to E.coli-derived asparaginase. The poster summarizes the safety results in 940 patients at participating U.S. oncology treatment centers between February 2006 and November 2011, when Erwinaze was available under a compassionate use protocol prior to its approval by the FDA in November 2011. The trial includes additional follow up data that further describe the incidence of adverse events associated with Erwinaze treatment, which are consistent with the known safety profile of Erwinaze.
News For JAZZ From The Last 14 Days
Check below for free stories on JAZZ the last two weeks.
Jazz Pharmaceuticals price target raised to $130 from $110 at UBS UBS raised its price target on Jazz Pharmaceuticals to adjust its discount rate to reflect a change in risk premium. The firm notes the company's business continues to perform above expectations and expects additional business activities to diversify the company. Shares are Buy rated.